Bioethical challenges with HIV treatment as prevention

Clinical Infectious Diseases

Volumn 59, Issue SUPPL.1, 2014, Pages

  Sugarman, Jeremy ^a,b,c  

^a JOHNS HOPKINS UNIVERSITY   (United States)

^b JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c JOHNS HOPKINS BLOOMBERG SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

ethics; HIV prevention; HIV treatment; policy

Indexed keywords

ANTIRETROVIRUS AGENT; HUMAN IMMUNODEFICIENCY VIRUS VACCINE; MICROBICIDE;

ARTICLE; BIOETHICS; CONDOM USE; HEALTH CARE; HEALTH CARE ACCESS; HEALTH CARE PLANNING; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; MEDICALIZATION; POST EXPOSURE PROPHYLAXIS; PRIORITY JOURNAL; RESOURCE ALLOCATION; SEXUALITY; HIV INFECTIONS;

ANTI-RETROVIRAL AGENTS; BIOETHICAL ISSUES; HIV INFECTIONS; HUMANS;

EID: 84904788682     PISSN: 10584838     EISSN: 15376591     Source Type: Journal    
DOI: 10.1093/cid/ciu246     Document Type: Article

References (16)

1. World Health Organization. Antiretroviral treatment as prevention (TasP) of HIV and TB: 2012 update. WHO/HIV/2012.12. Geneva, Switzerland, 2012. Available at: http://whqlibdoc.who.int/hq/2012/WHO-HIV-2012.12-eng.pdf. Accessed 30 November 2013.
2. Katz IT, Essien T, Marinda ET, et al. Antiretroviral therapy refusal among newly diagnosed HIV-infected adults. AIDS 2011; 25: 2177-81.
3. Haire B, Kaldor JM. Ethics of ARV based prevention: treatment-as- prevention and PrEP. Dev World Bioeth 2013; 13:63-9.
4. Simon AE, Wu AW, Lavori PW, Sugarman J. Preventive misconception: its nature, presence, and ethical implications for research. Am J Prev Med 2007; 32:370-4. (Pubitemid 46660442)
5. McNairy ML, Howard AA, El-Sadr WM. Antiretroviral therapy for prevention of HIV and tuberculosis: a promising intervention but not a panacea. J Acquir Immune Defic Syndr 2013; 63(Suppl 2):S200-7.
6. Fauci AS, Folkers GK. The world must build on three decades of scientific advances to enable a new generation to live free of HIV/AIDS. Health Aff (Millwood) 2012; 31:1529-36.
7. Bailey TC, Sugarman J. Social justice and HIV vaccine research in the age of pre-exposure prophylaxis and treatment as prevention. Curr HIV Res 2013; 11:473-80.
8. Towards an HIV cure: a global scientific strategy. International AIDS Society Scientific Working Group on HIV Cure-Deeks SG, Autran B, et al. Nat Rev Immunol 2012; 12:607-14.
9. Gallant JE, Mehta SH, Sugarman J. Universal antiretroviral therapy for HIV infection: should US treatment guidelines be applied to resourcelimited settings? Clin Infect Dis 2013; 57:884-7.
10. Haire B. Treatment-as-prevention needs to be considered in the just allocation of HIV drugs. Am J Bioeth 2011; 11:48-50.
11. Macklin R, Cowan E. Given financial constraints, it would be unethical to divert antiretroviral drugs from treatment to prevention. Health Aff (Millwood) 2012; 31:1537-44.
12. Brock DW,Wikler D. Ethical challenges in long-term funding for HIV/AIDS. Health Aff (Millwood) 2009; 28:1666-76.
13. Rennie S. Ethical use of antiretroviral resources for HIV prevention in resource poor settings. Dev World Bioeth 2013; 13:79-86.
14. Singh JA. Antiretroviral resource allocation for HIV prevention. AIDS 2013; 27:863-5.
15. Powers M, Faden R. Social justice: the moral foundations of public health and health policy. New York: Oxford University Press, 2006.
16. Wolff J, de-Shalit A. Disadvantage. New York: Oxford University Press, 2007.